- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Börsennews zur IMMUNOVIA Aktie und weiteren Hot Stocks erhalten | |||||
| 03.05. | Immunovia - Optimised hunting for the hidden killer | 35 | Edison Investment Research | During 2019, Immunovia will focus on optimising the IMMray PanCan-d test in preparation for the start of a commercial private testing service for pancreatic cancer (PDAC). The sample optimisation study... ► Artikel lesen | |
| 26.04. | Immunovia - Report from AGM | 27 | PR Newswire | STOCKHOLM, April 26, 2019 /PRNewswire/ -- The Annual General Meeting (AGM) of Immunovia AB (publ), corporate identity number 556730-4299 was held at Gamla Gästmatsalen in Medicon Village... ► Artikel lesen | |
| 24.04. | Immunovia Interim Report, January-March 2019 | 51 | PR Newswire | STOCKHOLM, April 24, 2019 /PRNewswire/ -- During the first quarter of 2019, we remained focused on our product launch strategy and continued to create value, as we reached several key objectives... ► Artikel lesen | |
| 10.04. | Corrected: Immunovia and University College of London Sign Agreement to Expand Validation Studies of IMMray PanCan-d for Early Signs and Symptoms | 27 | PR Newswire | LUND, Sweden, April 10, 2019 /PRNewswire/ -- Immunovia today announced that Prof. Stephen Pereira and his team at the institute for Liver and Digestive Health, University College London (UCL)... ► Artikel lesen | |
| 04.03. | Immunovia Publishes the Annual Report for the Financial Year 2018 | 23 | PR Newswire | LUND, Sweden, March 4, 2019 /PRNewswire/ -- Immunovia has today published the annual report for 2018 in Swedish. It is available on Immunovia's website.
Mats Grahn, CEO, comments: "We... ► Artikel lesen | |
| 04.03. | Immunovia Provides an Update on the Optimization Work to Meet the Expected Performance for Commercialization of IMMray PanCan-d | 29 | PR Newswire | LUND, SWEDEN, March 4, 2019 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia") today announced an update on the optimization process to refine the algorithms and eliminate any potential variations... ► Artikel lesen | |
| 14.02. | Immunovia Full Year Report, January-December 2018 | 29 | PR Newswire | STOCKHOLM, Feb. 14, 2019 /PRNewswire/ --
Throughout 2018, we continued to build on our mission to develop and validate accurate bloodbased diagnostic tests that can make a real and... ► Artikel lesen | |
| 14.02. | Immunovia to Participate in Upcoming Investor Conferences in March | 20 | PR Newswire | LUND, Sweden, Feb. 14, 2019 /PRNewswire/ --
Immunovia AB today announced that Mats Grahn, Chief Executive Officer, will participate and host one-on-one investor meetings at the following... ► Artikel lesen | |
| 12.02. | Invitation to Presentation of Immunovia's Full Year Report 2018 on February 14, 2019 | 23 | PR Newswire | LUND, Sweden, Feb. 12, 2019 /PRNewswire/ --
Immunovia invites to a teleconference (in English) for investors, analysts and media on February 14, at 5:30 - 6:30 p.m. CET. Immunovia will... ► Artikel lesen | |
| 12.02. | Immunovia AB Announces Appointment of Senior Director of Investor Relations | 24 | PR Newswire | LUND, Sweden, Feb. 12, 2019 /PRNewswire/ --
(Nasdaq Stockholm: IMMNOV), to strengthen IR and shareholder communication Immunovia today announced that Julie Silber has joined as Director... ► Artikel lesen | |
| 13.11.18 | Immunovia Invited to Present at Jefferies 2018 London Healthcare Conference | 20 | PR Newswire | LUND, Sweden, Nov. 13, 2018 /PRNewswire/ -- Immunovia (Nasdaq Stockholm: IMMNOV), today announced that the Company has been invited to present at the Jefferies 2018 London Healthcare Conference... ► Artikel lesen | |
| 07.11.18 | Immunovia Interim Report January-September 2018 | 20 | PR Newswire | STOCKHOLM, Nov. 7, 2018 /PRNewswire/ -- Immunovia's IMMray platform for blood-based biomarker signatures offers exciting new opportunities to develop accurate diagnostic tests that can detect... ► Artikel lesen | |
| 06.11.18 | Immunovia Sponsors Primary Care Educational Symposium at Fenway Park in Honor of World Pancreatic Cancer Day | 25 | PR Newswire | MARLBOROUGH, Massachusetts, Nov. 6, 2018 /PRNewswire/ -- On November 15, 2018 Immunovia will sponsor a unique educational symposium for primary care clinicians in honor of World Pancreatic... ► Artikel lesen | |
| 05.11.18 | Invitation to Presentation of Immunovia's Interim Report January-September 2018 on November 7, 2018 | 29 | PR Newswire | LUND, Sweden, Nov 5, 2018 /PRNewswire/ -- Immunovia will publish the company's interim report for the period January-September 2018 on Wednesday, November 7, at 08:30 a.m. CET.
Immunovia... ► Artikel lesen | |
| 26.10.18 | Immunovia AB (Publ) Nomination Committee Appointed for AGM 2019 | 18 | PR Newswire | According to the instruction that was adopted at the Immunovia AB (Publ) AGM May 3 2018, the nomination committee should consist of four members
LUND, Sweden, Oct. 26, 2018 /PRNewswire/... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOFEM BIOSCIENCES | 4,320 | -4,32 % | PDL BioPharma - Eyes focused on Evofem | In June, PDL invested the second and final tranche of $30m ($60m in total) in Evofem, a women's health company that is preparing to submit an NDA for Amphora, a non-hormonal female contraceptive, in... ► Artikel lesen | |
| ATOSSA GENETICS | 1,550 | -1,90 % | Atossa Genetics Inc.: Interview With Atossa Genetics Founder & CEO Steven Quay MD, Ph.D. Over Gynecomastia | SAN FRANCISCO, CA / ACCESSWIRE / October 15, 2019 / Recently, Steven Quay MD, Ph.D., Founder, Chairman and CEO of Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing... ► Artikel lesen | |
| TELADOC HEALTH | 62,24 | -1,69 % | Warum die Aktie von Teladoc Health im September um 17 % gestiegen ist | Was war los? Die Aktien von Teladoc Health (WKN:A14VPK) stiegen nach Angaben von S&P Global Market Intelligence im vergangenen Monat um 17 %. Grund dafür waren eine Reihe von Mitteilungen, die darauf... ► Artikel lesen | |
| DEXCOM | 138,94 | -1,31 % | DexCom: A Leader In A Lucrative Market But May Be A Little Overvalued | ||
| CYTOSORBENTS | 4,214 | +1,79 % | Cytosorbents (CTSO) Investor Presentation - Slideshow | ||
| EMPOWER CLINICS | 0,044 | +17,84 % | Empower Clinics: Heritage-Joint Venture soll CBD-Strategie beschleunigen | Wie wir berichteten, hat Empower Clinics (CSE CBDT / FRA 8EC) vor Kurzem eine CBD-Extraktionsanlage in Oregon in Besitz genommen. Um deren Inbetriebnahme zu beschleunigen und die Effizienz zu erhöhen... ► Artikel lesen | |
| EKSO BIONICS | 0,550 | +19,05 % | Ekso Bionics Holdings, Inc.: Ekso Bionics to Present at the Cantor Fitzgerald Global Healthcare Conference on ... | ||
| IMAGIN MEDICAL | 0,029 | -10,15 % | Imagin Medical Inc: Imagin begins social media campaigns | ||
| MILLENDO THERAPEUTICS | 6,400 | -3,03 % | Millendo Therapeutics Announces 21st European Congress of Endocrinology 2019 Presentations on Livoletide for Prader-Willi Syndrome and Nevanimibe for Classic Congenital Adrenal Hyperplasia | Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that its late-stage clinical... ► Artikel lesen | |
| INTERPACE DIAGNOSTICS | 0,710 | 0,00 % | Interpace Diagnostics Group, Inc.: Interpace Announces Closing of $13 Million Second Tranche Acquisition Financing ... | ||
| STAAR SURGICAL | 25,800 | +4,03 % | STAAR Surgical Celebrates Visual Freedom with Jorgensen Family | Ophthalmologist Jorn S. Jorgensen, CEO and Founder of EuroEyes, Implanted EVO ICLs in His Son, Jannik Jorgensen
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer... ► Artikel lesen | |
| CANCER GENETICS | 0,123 | -6,11 % | Datar Cancer Genetics meldet positive Ergebnisse mit einer objektiven Ansprechrate von 42,9 % und einer Krankheitskontrollrate von 90,5 % bei stark vorbehandelten Patienten mit dem ultrapersonalisierten Pan-Krebs-Behandlungsprotokoll in der klinischen... | London (uk), Mumbai (indien), und Bayreuth (deutschland) (ots/PRNewswire) - - Das RESILIENT Protokoll analysiert umfassend die Eigenschaften von Tumoren und nutzt künstliche Intelligenz (KI) zur Therapieoptimierung... ► Artikel lesen | |
| INVITAE | 15,500 | -6,06 % | InVitae Shares Bounce Back Following Analyst Rebuttal To Short Seller Allegations | ||
| SENSEONICS | 0,913 | +7,13 % | Senseonics touts Eversense reimbursement win | ||
| NANOSONICS | 4,180 | -2,79 % | NANOSONICS LIMITED: Notice of Annual General Meeting/Proxy Form |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
